GMED PE Ratio & Valuation, Is GMED Overvalued

Historical Valuation

Globus Medical Inc (GMED) is now in the Fair zone, suggesting that its current forward PE ratio of 21.59 is considered Fairly compared with the five-year average of 25.96. The fair price of Globus Medical Inc (GMED) is between 87.15 to 130.65 according to relative valuation method.

Relative Value

Fair Zone

87.15-130.65

Current Price：87.57

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Globus Medical Inc (GMED) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Globus Medical Inc (GMED) has a current Price-to-Book (P/B) ratio of 2.67. Compared to its 3-year average P/B ratio of 2.32, the current P/B ratio is approximately 14.98% higher. Relative to its 5-year average P/B ratio of 3.06, the current P/B ratio is about -12.80% higher. Globus Medical Inc (GMED) has a Forward Free Cash Flow (FCF) yield of approximately 4.96%. Compared to its 3-year average FCF yield of 3.18%, the current FCF yield is approximately 56.09% lower. Relative to its 5-year average FCF yield of 2.90%, the current FCF yield is about 71.30% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for GMED competitors is 4.18, providing a benchmark for relative valuation. Globus Medical Inc Corp (GMED.N) exhibits a P/S ratio of 3.80, which is -9.06% above the industry average. Given its robust revenue growth of 25.73%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of GMED increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of GMED in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is GMED currently overvalued or undervalued?

What is Globus Medical Inc (GMED) fair value?

GMED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Globus Medical Inc (GMED) is between 87.15 to 130.65 according to relative valuation method.

How does GMED's valuation metrics compare to the industry average?

The average P/S ratio for GMED's competitors is 4.18, providing a benchmark for relative valuation. Globus Medical Inc Corp (GMED) exhibits a P/S ratio of 3.80, which is -9.06% above the industry average. Given its robust revenue growth of 25.73%, this premium appears sustainable.

What is the current P/B ratio for Globus Medical Inc (GMED) as of Mar 11 2026?

As of Mar 11 2026, Globus Medical Inc (GMED) has a P/B ratio of 2.67. This indicates that the market values GMED at 2.67 times its book value.

What is the current FCF Yield for Globus Medical Inc (GMED) as of Mar 11 2026?

As of Mar 11 2026, Globus Medical Inc (GMED) has a FCF Yield of 4.96%. This means that for every dollar of Globus Medical Inc's market capitalization, the company generates 4.96 cents in free cash flow.

What is the current Forward P/E ratio for Globus Medical Inc (GMED) as of Mar 11 2026?

As of Mar 11 2026, Globus Medical Inc (GMED) has a Forward P/E ratio of 21.59. This means the market is willing to pay $21.59 for every dollar of Globus Medical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Globus Medical Inc (GMED) as of Mar 11 2026?

As of Mar 11 2026, Globus Medical Inc (GMED) has a Forward P/S ratio of 3.80. This means the market is valuing GMED at $3.80 for every dollar of expected revenue over the next 12 months.

GMED Valuation